A new systematic review published in the International Journal of Molecular Sciences explores the potential role of cannabidiol (CBD)-rich cannabis in managing symptoms of autism spectrum disorder (ASD).
The study, conducted by researchers from LUM University, G. d’Annunzio University, and the Università Politecnica delle Marche, highlights both the promise and the limitations of this emerging treatment.
ASD is a lifelong neurological condition with limited treatment options, driving interest in alternative therapies such as phytocannabinoids derived from cannabis. This review assessed studies from 2020 onward that focused on individuals with ASD treated with CBD-rich cannabis. Researchers analyzed data from four studies involving 353 participants across Israel, Turkey, and Brazil.
The studies revealed improvements in behavioral symptoms, social responsiveness, and communication. However, cognitive improvements were less consistent. Dosages often combined CBD with trace amounts of THC, and the treatment durations varied widely. While many participants experienced mild side effects such as somnolence and reduced appetite, with a few reporting more severe reactions, including increased aggression, which led to treatment discontinuation in a few cases.
Researchers conclude by saying “CBD-rich cannabis shows promise in improving behavioral symptoms associated with ASD. However, variations in study designs, dosages, and outcome measures highlight the need for standardized assessment tools and further research to understand pharmacological interactions and optimize treatment protocols. Despite the mild adverse effects observed, larger, well-controlled trials are necessary to establish comprehensive safety and efficacy profiles.”
